Study Type
Interventional - Procedure
completed
The research question for the C-CUSP ED study was: Does a multidisciplinary emergency department (ED)-based intervention, using patient educational materials and prescription of novel oral anticoagulant (NOAC) with immediate follow-up by a community-based clinic dedicated to the care of atrial fibrillation (AF), improve emergency physician prescription of new NOAC for patients presenting to the emergency department with AF?
Primary endpoint:
The rate of new oral anticoagulant (OAC) prescriptions at emergency department discharge in patients with atrial fibrillation who are OAC eligible but were not on OAC at ED presentation.
Ratika Parkash, of the Nova Scotia Health Authority, was a co-Principal Investigator on the C-CUSP ED
Study Design
Multicentre pragmatic 3-phase implementation
NO. of Countries
1
NO. of Sites
3
NO. of Participants
631
Study Period
2015 - 2017
Sponsor
PHRI
Jeff Healey
Senior Scientist
Jeff Healey
Senior Scientist
Jeff Healey is a Cardiologist/Electrophysiologist and Professor of Medicine at McMaster University. He is Yusuf Chair and Director of Cardiology at McMaster University. He is the chair of the Canadian Stroke Prevention and Intervention Network (CSPIN) and past chair of the Canadian Atrial Fibrillation guidelines committee. He is also on the steering committee of the international AF Screen organization.
Healey was the lead author of the ASSERT trial that demonstrated the increased stroke risk associated with sub-clinical atrial fibrillation (New England Journal of Medicine 2012), and the principal investigator of the ARTESIA trial, which demonstrated that anticoagulation with apixaban reduced the risk of stroke in patients with sub-clinical atrial fibrillation New England Journal of Medicine 2023). He is also the principal investigator of the LAAOS-4 trial, evaluating the role of left atrial appendage occlusion on top of NOAC therapy for prevention of stroke in high-risk individuals with atrial fibrillation.
